Eloxx Pharmaceuticals, Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.66. It usually reports 3–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on how many days after a quarter ends the company has reported recently. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 3–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 11, 2026
42 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-5
|
-0.66
|
|
Nov 13, 2023
44 days after quarter end
|
Q3 FY2023
ended Sep 30, 2023
|
—
|
-4
+52.2%
|
-1.31
+62.2%
|
|
Apr 3, 2023
3 days after quarter end
|
Q1 FY2023
ended Mar 31, 2023
|
—
|
-6
+46.4%
|
-2.88
|
|
Nov 14, 2022
45 days after quarter end
|
Q3 FY2022
ended Sep 30, 2022
|
—
|
-8
+24.0%
|
-3.47
|
|
Aug 15, 2022
46 days after quarter end
|
Q2 FY2022
ended Jun 30, 2022
|
—
|
-11
+70.6%
|
-4.90
|
|
Apr 4, 2022
4 days after quarter end
|
—
ended Mar 31, 2022
|
—
|
—
|
—
|
|
Nov 9, 2021
40 days after quarter end
|
—
ended Sep 30, 2021
|
—
|
—
|
—
|
|
Aug 17, 2021
48 days after quarter end
|
—
ended Jun 30, 2021
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ELOX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Arlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1035354
- Former names
- Sevion Therapeutics, Inc. (until Dec 22, 2017); SENESCO TECHNOLOGIES INC (until Sep 29, 2014); NAVA LEISURE USA INC (until May 24, 1999)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.